Sausan A. Moharram
Medicon Village
Lund, M, Sweden
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Corrigendum to "The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)" [Cancer Lett. 392 (1) (2017) 9-16].
Journal: Cancer letters
Published: June 09, 2019
Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.
Journal: NPJ genomic medicine
Published: December 31, 2018
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia.
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia.
Journal: Blood cancer journal
Published: November 23, 2018
Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.
Journal: Clinical epigenetics
Published: January 23, 2018
SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.
Journal: Scientific reports
Published: October 27, 2017
T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways.
Journal: Journal of Cancer
Published: July 02, 2017
ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.
Journal: Oncotarget
Published: November 10, 2016
Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
Journal: Cellular and molecular life sciences : CMLS
Published: October 12, 2016
Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.
Journal: Oncotarget
Published: May 27, 2016
Last Updated: 09/26/2026